X
Record #45298

Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas

Original paper date
Oct 16, 2021
Institution
Department of Malignant Hematology and Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33613, USA · Molecular Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33613, USA · Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33613, USA · Department of Immunology and Malignant Hematology, Tianjin Cancer Hospital, Tianjin 300060, China · The Drug Discovery, Delivery and Experimental Therapeutics, University of Kansas Cancer Center, Kansas City, KS 66160, USA · Dana-Farber Cancer Institute, Boston, MA 02115, USA · Department of Pathology, University of Nebraska Medical Center, Omaha, NE 68198, USA · Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA · Department of Pathology, Weill-Cornell Medical College, New York, NY 10065, USA
Open access
No
Article type
Research Article
Broad categories
(BLS) Biology - Cancer(BLS) Biology - Cellular(BLS) Genetics
Citation lifecycle

How this paper is being cited

Pre-retraction
246
Same day
0
Post-retraction
10
% post-retraction
3.9%
~148.8 citations/yr before retraction · ~3.1 citations/yr after
— citing papers

Who is still citing this work

Loading…
Back to browse